Adial Pharmaceuticals (ADIL) announced the submission of the AD04 product application for consideration of the FDA Commissioner’s National Priority Voucher Pilot Program. Announced in 2025, the CNPV program is designed to speed up the FDA review process for drugs that address one of five key U.S. national health priorities. It uses a collaborative review approach-similar to a “tumor board,” where experts meet to discuss cases-to help evaluate applications more efficiently.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ADIL:
- Adial Pharmaceuticals completes AD04 demonstration batch production
- Adial Pharmaceuticals Implements New Executive Equity Compensation Plan
- Adial Pharmaceuticals expects cash to fund operations into 2H of 2026
- Adial Pharmaceuticals Secures European Partnership for AD04 Commercialization
- Adial Pharmaceuticals enters collaboration framework agreement with Molteni